Portage Biotech (ALP) Stock Price, News & Analysis

Company Overview

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions. Its business model emphasizes strategic licensing, partnering and potential out‑licensing to accelerate development and access external expertise and commercialization channels. The company frequently works with academic investigators, contract research organizations and industry partners to progress programs through translational proof‑of‑concept and later-stage studies.

As a publicly traded company, Portage leverages capital markets and corporate development activities—such as licensing and acquisitions—to build and de‑risk its portfolio. The company engages with clinical and regulatory networks in multiple jurisdictions as it advances programs, and investors seeking detailed information on specific assets, leadership or geographic presence should consult Portage’s regulatory filings and investor materials for the most current disclosures.

Key Stats

• Today's Range: $0.10 to $0.11
• 50-Day Range: $0.10 to $0.33
• 52-Week Range: $0.10 to $13.80
• Volume: 3.21 million shs
• Average Volume: 10.19 million shs
• Market Capitalization: $2.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.25
• Consensus Rating: Reduce

Portage Biotech Stock Analysis - MarketRank™

Portage Biotech scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Reduce

Consensus Rating

Portage Biotech has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Portage Biotech has a consensus price target of $0.25, representing about 132.1% upside from its current price of $0.11.

Amount of Analyst Coverage

Portage Biotech has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Portage Biotech are expected to grow in the coming year, from ($0.28) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Portage Biotech is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Portage Biotech is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Portage Biotech has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.04% of the float of Portage Biotech has been sold short.

Short Interest Ratio / Days to Cover

Portage Biotech has a short interest ratio ("days to cover") of 0.26, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Portage Biotech has recently increased by 273.70%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Portage Biotech does not currently pay a dividend.

Dividend Growth

Portage Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Portage Biotech this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for ALP on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Portage Biotech insiders have not sold or bought any company stock.

Percentage Held by Institutions

13.36% of the stock of Portage Biotech is held by institutions.

Company Calendar

• Last Earnings: 7/16/2026
• Today: 9/08/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Technology
• Industry: IT Services
• Sub-Industry: Internet Services & Infrastructure
• Current Symbol: NASDAQ:ALP
• Previous Symbol: NASDAQ:ATON
• CIK: 1095435
• Web: portagebiotech.com
• Phone: (416) 737-7600
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Portage Biotech: $0.25
• High Price Target: $0.25
• Low Price Target: $0.25
• Potential Upside/Downside: +132.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 0.31
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: $100 thousand
• Price / Sales: 25.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 0.38

Miscellaneous

• Outstanding Shares: 23,470,000
• Free Float: N/A
• Market Cap: $2.53 million
• Optionable: N/A
• Beta: 0.54